Search results
Author(s):
Hans-Peter Brunner-La Rocca
,
Sandra Sanders-van Wijk
Added:
3 years ago
Natriuretic peptides (NPs) are well established in the diagnostic process of heart failure (HF). Low levels of NPs are particularly useful to exclude heart failure (HF). Numerous studies, predominantly in patients presenting with acute onset of symptoms suspected of HF, have convincingly shown the value of NPs in this regard. A meta-analysis published in 2015 clearly summarised the value of brain…
View more
Author(s):
Noel S Lee
,
Lori B Daniels
Added:
3 years ago
Today, natriuretic peptides are ubiquitously utilized for the diagnosis, treatment, and prognostication of heart failure in the Emergency Department, as well as inpatient and outpatient settings alike.1–5 These endogenous hormones counteract some of the most detrimental effects of heart failure. Given their clinical and physiological importance, the fact that a manuscript describing the…
View more
Author(s):
Hans-Peter Brunner-La Rocca
,
Sema Bektas
Added:
3 years ago
Although the first study on biomarker-guided therapy of chronic heart failure (HF) was published 15 years ago,1 there is still no real proof of the superiority of this approach as compared with standard therapy. The guidelines of the European Society of Cardiology simply state that: “several RCTs that evaluated natriuretic peptide-guided treatment (intensifying treatment in order to lower peptide…
View more
Author(s):
Sriram D Rao
,
Srinath Adusumalli
,
Jeremy A Mazurek
Added:
3 years ago
In the article by Rao et al. entitled Pulmonary Hypertension in Heart Failure Patients (Cardiac Failure Review 2020;6:e05. https://doi.org/10.15420/cfr.2019.09), the following correction should be made.
The authors incorrectly stated that higher TAPSE/PASP correlates with “higher levels of natriuretic peptides, worse systemic and pulmonary haemodynamics and abnormal exercise aerobic capacity”,…
View more
Author(s):
A Mark Richards
Added:
3 years ago
Ideally biomarkers provide the clinician with assistance in one or more of: (i) diagnosis, (ii) prognosis, (iii) choice and titration of therapy, (iv) monitoring progression of disease and (v) assessing response to treatment. The best-established biomarkers in acute decompensated heart failure (ADHF) are the B-type natriuretic peptides (brain natriuretic peptide [BNP] and N-terminal of the…
View more
Foreword
Author(s):
Andrew JS Coats
,
Giuseppe Rosano
Added:
3 years ago
Article
A Mark Richards
Research Area(s) / Expertise:
Job title: Director of the Christchurch Heart Institute
Author
Author(s):
Sunil K Nadar
,
Muhammad Mujtaba Shaikh
Added:
3 years ago
The National Institutes of Health Biomarkers Definitions Working Group define a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.1 Biomarkers have become increasingly important in current medical practice as they offer an easy way to either…
View more
Author(s):
Milton Packer
Added:
3 years ago
Patients with a broad range of systemic inflammatory rheumatic diseases (i.e. rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis and ankylosing spondylitis) are exceptionally prone to cardiovascular disorders, but previous work concerning the development of heart disease in these individuals has largely focused on the risk of MI.
However, the most important cardiovascular…
View more